Dmitry Samarsky, an expert in the field of oligonucleotide medicines, has joined Silence Therapeutics Plc as chief scientific officer to help oversee the development of RNA therapeutics for serious diseases. Dr Samarsky joins the company from OliX Pharmaceuticals Inc in South Korea where he was senior vice president of technology and global business development. He holds a BSc in biochemistry from the National University of Lviv in Ukraine and a PhD in biochemistry and molecular biology from the University of Massachusetts.
Also joining Silence as a non-executive director is Andy Richards, a specialist UK entrepreneur and investor. Dr Richards is also a director of Cancer Research Technology Ltd.
Silence announced the appointment on 5 September 2016.
Copyright 2016 Evernow Publishing Ltd